Last updated 17 September 2019
We commit to ensuring the quality, safety and reliable supply of our products. If the supply of our medicines or vaccines is disrupted in Australia we will publish details here.
GSK is currently experiencing a supply shortage of its rabies vaccine, Rabipur (inactivated rabies virus vaccine). This supply shortage is due to an unexpected increase in demand and is not related to vaccine quality or safety
The shortage impacts those who wish to purchase Rabipur for pre-exposure prophylaxis for example, those travelling to countries where rabies is present and where they may be interacting with animals.
GSK understands that all State and Territory Health Departments stockpile rabies vaccines (including Rabipur) for post-exposure prophylaxis (that is, for those individuals who have received an animal wound and are considered to be at risk of rabies). We are working with the States and Territories to maintain these emergency post-exposure stockpiles.
If you have any concerns about your own exposure to rabies, please contact a Healthcare Professional.
Supply update for measles, mumps, rubella and varicella-containing vaccine
GSK will experience a supply constraint of its measles, mumps, rubella & varicella (MMRV) combination vaccine, Priorix Tetra, from the beginning of May to the end of October 2019.
This shortage will impact our ability to supply Priorix Tetra to the National Immunisation Program (NIP) and to non-government customers. GSK has worked with the Commonwealth Department of Health to ensure that an alternative MMRV vaccine will be available during this time, ensuring no impact to children’s immunisations as part of the NIP.
Hepatitis A-containing vaccines
GSK is experiencing supply constraint of Havrix Junior - inactivated hepatitis A virus vaccine. This supply constraint is due to manufacturing capacity and is not related to vaccine quality or safety. Supply of other hepatitis vaccines is unaffected.
Herpes zoster vaccine
GSK’s herpes zoster vaccine, Shingrix, is not available in Australia. There is currently no confirmed timing for the supply of Shingrix to Australia.
Fluarix Tetra is now only available for government programs
The significant number of influenza notifications so early this season compared to other years has driven a significant increase in demand for GSK’s seasonal influenza vaccine, Fluarix Tetra. GSK has already released a large amount of its reserve doses into the private market, with this year being the largest private market allocation of doses compared to previous years.
GSK has received urgent requests from governments for additional doses, particularly for the vaccination of children under five years of age. Consequently, GSK has taken the decision to divert all of its remaining Fluarix Tetra vaccine doses to these important programs.
For clarity, all government program supplies of Fluarix Tetra are secure and have either been delivered, or are planned to be, in the next few weeks.
Customers should note that there are alternative seasonal influenza vaccines produced by other suppliers that may still be available for private market supply until notified otherwise.
Ventolin (salbutamol sulfate) 5mg/2.5mL nebules
GSK is experiencing a supply constraint of its Ventolin 5mg nebules. This is due to high global demand for the product, with local demand also increasing due to an alternative brand of salbutamol inhalation ampoules being out of stock in Australia. We anticipate intermittent supply throughout 2019.
This supply constraint does not affect other Ventolin products, including Ventolin Metered Dose Inhalers (also known as ‘puffers’) which continue to be in supply.
Please visit the TGA website for ongoing updates to supply.
For more information on GSK's medicines or vaccines, please contact GSK medical information on 1800 033 109.